Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobul

Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia disorders.

Related Keywords

Japan , United States , Japanese , America , , Japanese Ministry Of Health , Takeda Pharmaceutical Co , Takeda Pharmaceutical , Japanese Ministry , North America , Makeda , Primary Immunodeficiency , Cuvitru , Oak , Hypogammaglobulinemia , Uvitru Subcutaneous Immunoglobulin , Secondary Immunodeficiency , Agammaglobulinemia ,